EU Countries Slam Transferable Exclusivity Voucher Proposal
Executive Summary
A group of EU member states has written to the European Commission saying that an exclusivity voucher scheme intended to stimulate R&D into new antimicrobials will stifle innovation by competitor companies and push up costs for national health systems.
You may also be interested in...
Off-Patent Industry Proposes Extensions To EU Market Protection Rather Than Data Exclusivity
Medicines for Europe proposed several alterations to the European Commission’s planned changes to exclusivity incentives at its recent Regulatory and Pharmacovigilance Conference in Brussels, most notably suggesting that the proposed extensions to data exclusivity should instead apply to market exclusivity.
EU Ministers Endorse ‘Multi-Country Pull Incentive’ For New Antimicrobial R&D
Although it is not legally binding, a recommendation endorsed this week by the Council of the EU will give countries more tools to tackle the thorny problem of resistance to antimicrobial drugs, according to the Swedish presidency of the council.
EU Plans To Trial Antimicrobial Voucher Scheme For 15 Years
Proposals for an EU voucher that would encourage the development of “game-changing” antimicrobials are accompanied by plans for procurement mechanisms to guarantee revenues for companies regardless of sales volumes. But one law firm said the conditions attached to the voucher were so strict that the scheme appeared “unworkable.”